Matthew Kelly, MD

My research is broadly focused on elucidating the complex interactions that exist between the host microbiome and exogenous pathogens that cause infections in children. We have several ongoing projects evaluating: 1) the impact of the upper respiratory microbiome on the risk of colonization and invasion by bacterial respiratory pathogens among infants in Botswana; 2) associations between the gut microbiome of pediatric stem cell transplant recipients and the risk of infections (bloodstream infection, C. difficile infection) and graft-versus-host disease; and 3) the role of the gut and respiratory microbiomes in mediating COVID-19 infection susceptibility and disease severity in children. Ultimately, I aim to develop strategies that use targeted modification of the microbiome for the prevention of infections in children.
Education and Training
- Pediatric Infectious Diseases Fellowship, Pediatrics, Duke University School of Medicine, 2013 - 2016
- David N. Pincus Pediatric Global Health Fellowship, Pediatrics, Children's Hospital of Philadelphia, 2011 - 2013
- Internship/Residency, Pediatrics, Children's Hospital Boston, 2007 - 2010
- M.D., Harvard Medical School, 2007
- M.P.H., Harvard University , 2007
Selected Grants and Awards
- Unified Program for Therapeutics in Children
- Clinical and gut microbial risk factors for Gram-negative bacterial late-onset sepsis among premature infants in Singapore
- Nasopharyngeal Microbiome and Risk of Bacterial Pathogen Colonization in Infants
- PTN 2.0 Task Order 7 HIV Lactation
- A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of a Single Infusion of Bezlotoxumab (MK-6072, Human Monoclonal Antibody to C. difficile Toxin B) in Children Aged 1 to
- The serotype epidemiology and antibiotic resistance of Streptococcus pneumoniae in Botswana following introduction of 13-valent pneumococcal conjugate vaccine
- VTEU Task C Option 2 Protocol 14-0079.B1C1.0028
- LOC-IMPAACT Leadership Group-IMPAACT 2018 Protocol Co-Vice Chair
- A Phase 1b, Open-label Single dose study to Evaluate the Pharmacokinetics, Safety and Tolerability of MK-7655A in Pediatric Subjects from Birth to less than 18 years of Age with Confirmed or Suspected Gramnegative Infections
- The effect of household air pollution on the health outcomes of infants in Botswana
- The impact of HIV infection or exposure on the upper respiratory microbiome of children in Botswana
- Fungal biomarkers for diagnosis and response to therapy for pediatric candidemia
- LOC-IMPAACT Leadership Group-IMPAACT 2018 Protocol Vice Chair support
- RFTP 2016 CISA 03 - Option 1 - Fever after Simultaneous Vaccination (Lead)
- American Society of Tropical Medicine and Hygiene
- Multi-center studies to improve diagnosis and treatment of pediatric candidiasis
- VTEU Task C Option 1 Protocol 14-0079.B1C1.0028
- RFTP 2016 CISA 03 - Base - Fever after simultaneous vaccination (Lead)
- VTEU Task B Base Protocol 14-0079.B1C1.0028
- The Effect of In Utero Exposure to HIV and Antiretroviral Therapy on the Microbiology and Outcomes of Severe Pneumonia